UPDATED Jun 23, 2024
All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | US$883.88 | -0.1% | 95.2% | US$795.9b | US$855.39 | PE129.7x | E27.3% | 0.6% | Pharmaceuticals & Biotech | ||
UNH | US$482.59 | -1.4% | 0.7% | US$444.2b | US$575.77 | PE28.9x | E19.7% | 1.7% | Healthcare | ||
JNJ | US$148.75 | 2.2% | -10.1% | US$358.0b | US$171.72 | PE21x | S4.4% | 3.3% | Pharmaceuticals & Biotech | ||
MRK | US$130.72 | 2.5% | 15.6% | US$331.1b | US$142.68 | PE143.6x | E23.7% | 2.4% | Pharmaceuticals & Biotech | ||
ABBV | US$170.39 | 1.1% | 25.4% | US$300.9b | US$183.24 | PE50.6x | E23.0% | 3.6% | Pharmaceuticals & Biotech | ||
AZN | UK£124.72 | 0.4% | 10.4% | UK£193.3b | UK£136.65 | PE38.6x | E14.7% | 2.0% | Pharmaceuticals & Biotech | ||
TMO | US$564.60 | -0.6% | 8.2% | US$215.5b | US$629.47 | PE35.7x | E10.6% | 0.3% | Pharmaceuticals & Biotech | ||
DHR | US$254.96 | 0.3% | 7.2% | US$188.8b | US$273.31 | PE46.4x | E13.8% | 0.4% | Pharmaceuticals & Biotech | ||
ABT | US$105.72 | 2.2% | -2.6% | US$183.9b | US$125.16 | PE32.8x | E11.3% | 2.1% | Healthcare | ||
AMGN | US$308.16 | 1.6% | 37.1% | US$165.3b | US$316.44 | PE43.9x | E18.2% | 2.9% | Pharmaceuticals & Biotech | ||
PFE | US$27.74 | 2.8% | -24.8% | US$157.2b | US$31.92 | PS2.9x | E30.6% | 6.1% | Pharmaceuticals & Biotech | ||
ISRG | US$432.56 | 0.6% | 33.0% | US$153.4b | US$426.49 | PE77.2x | E11.7% | n/a | Healthcare | ||
SYK | US$342.64 | -0.6% | 15.4% | US$130.5b | US$372.94 | PE38.8x | E10.5% | 0.9% | Healthcare | ||
ELV | US$534.42 | 0.007% | 19.1% | US$124.2b | US$607.19 | PE19.9x | E12.1% | 1.2% | Healthcare | ||
VRTX | US$468.71 | -1.1% | 34.9% | US$121.0b | US$463.42 | PE30.1x | E10.4% | n/a | Pharmaceuticals & Biotech | ||
BSX | US$77.71 | 2.0% | 45.3% | US$114.2b | US$82.35 | PE64.7x | E18.1% | n/a | Healthcare | ||
REGN | US$1,053.14 | 0.7% | 34.3% | US$113.6b | US$1,051.47 | PE29.5x | E12.5% | n/a | Pharmaceuticals & Biotech | ||
MDT | US$81.64 | 2.1% | -6.2% | US$104.7b | US$94.03 | PE28.5x | E12.8% | 3.4% | Healthcare | ||
CI | US$339.98 | 1.8% | 23.0% | US$96.6b | US$392.04 | PE26.7x | E17.6% | 1.6% | Healthcare | ||
CSL | AU$292.01 | 1.1% | 4.3% | AU$141.6b | AU$307.59 | PE37.9x | E14.7% | 1.2% | Pharmaceuticals & Biotech | ||
HCA | US$338.92 | 0.4% | 14.7% | US$88.8b | US$351.29 | PE16.2x | E6.0% | 0.8% | Healthcare | ||
GILD | US$70.67 | 10.0% | -7.7% | US$88.0b | US$82.89 | PE181.5x | E36.2% | 4.4% | Pharmaceuticals & Biotech | ||
BMY | US$41.93 | 2.3% | -35.3% | US$85.0b | US$53.19 | PS1.9x | E44.7% | 5.7% | Pharmaceuticals & Biotech | ||
GSK | UK£15.99 | -0.06% | 12.6% | UK£65.2b | UK£20.36 | PE14.5x | E12.4% | 3.6% | Pharmaceuticals & Biotech |